Catch me, if you can!

ging heart rate during treatment of hypertension on incidence of heart failure. Am J Cardiol 2012;109:699–704. 10. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, Devereux RB. Allcause, cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010;31:2271–2279. 11. Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Devereux RB. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhythmia Electrophysiol 2008;1:337–343. 12. Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, Brunner HR, Mancia G, Schork MA, Hua TA, Holzhauer B, Zappe D, Majahalme S, Jamerson K, Koylan N. Heart rate predicts cardiac events in treated high risk hypertension. Am J Cardiol 2012;109:685–692. 13. Fox K, Ford I, Tendera M, Ferrari R, on behalf of the BEAUTIFUL investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807–816. 14. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubrost-Brama A, Lerebours G, Tavazzi L, on behalf of the SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376: 886–894. 15. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubrost-Brama A, Lerebours G, Tavazzi L, on behalf of the SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875–885.